Medicus Pharma director gets 50,000 share options

Medicus Pharma Ltd. director Robert J. Ciaruffoli received a grant of stock options covering 50,000 common shares.

Rhea-AI Filing Summary

Medicus Pharma Ltd. director Robert J. Ciaruffoli received a grant of stock options covering 50,000 common shares. The options have an exercise price of $0.36 per share, were granted on June 3, 2026, and are scheduled to vest quarterly in four equal installments over one year.

These options expire on June 3, 2031, and represent 50,000 derivative securities held by Ciaruffoli following this compensation-related award. The filing reports no open-market purchases or sales of Medicus Pharma common shares.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 1 txn

Insider Ciaruffoli Robert J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	50,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 50,000 contracts (Direct)

Footnotes (1)

1. F1. The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

Key Figures

Option grant size: 50,000 options Exercise price: $0.36 per share Underlying shares: 50,000 common shares +4 more

7 metrics

Option grant size 50,000 options Stock Option (right to buy) granted to director

Exercise price $0.36 per share Conversion or exercise price of granted options

Underlying shares 50,000 common shares Underlying security shares for the option grant

Post-grant derivative holdings 50,000 options Total derivative securities following transaction

Grant date June 3, 2026 Option grant date per footnote

Expiration date June 3, 2031 Option expiration date

Vesting schedule Quarterly over one year Four equal installments per footnote

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, derivative securities, vest quarterly, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

derivative securities financial

"derivativeTransactionCount: 1 derivative-type records"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

vest quarterly financial

"The option is scheduled to vest quarterly in four equal installments"

expiration date financial

"expiration_date: 2031-06-03T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Medicus Pharma (MDCX) report in this Form 4 filing?

Medicus Pharma reported that director Robert J. Ciaruffoli received a grant of stock options for 50,000 common shares. These options are a compensation-related award rather than an open-market share purchase or sale.

How many Medicus Pharma (MDCX) options were granted to Robert J. Ciaruffoli?

Robert J. Ciaruffoli was granted stock options covering 50,000 Medicus Pharma common shares. The option award increases his derivative holdings to 50,000 options, according to the post-transaction balance reported in the Form 4 filing.

What is the exercise price and expiry of the new Medicus Pharma (MDCX) options?

The granted stock options have an exercise price of $0.36 per Medicus Pharma common share and expire on June 3, 2031. This gives the director a multi-year right to purchase shares at that fixed price if the options vest.

How do the Medicus Pharma (MDCX) options granted to the director vest?

The options granted to director Robert J. Ciaruffoli are scheduled to vest quarterly in four equal installments over one year. This means 25% of the 50,000 options vest every quarter during the first year after the June 3, 2026 grant date.

Did the Medicus Pharma (MDCX) director buy or sell any shares in the market?

The Form 4 does not report any open-market purchases or sales of Medicus Pharma common shares by the director. It only shows an acquisition of stock options as a grant or award, classified as a derivative transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ciaruffoli Robert J.

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.36	06/03/2026		A		50,000		(1)	06/03/2031	Common Shares	50,000	$0	50,000	D

Explanation of Responses:

1. The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

	/s/ Raza Bokhari, as Attorney-in-Fact, for Robert J. Ciaruffoli	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)